

27 June 2023

**Roquefort Therapeutics plc**  
("Roquefort Therapeutics" or the "Company")

**Investor Presentation via Investor Meet Company**

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, announces that CEO Ajan Reginald and Chairman Stephen West will give a live presentation via the Investor Meet Company platform at **11am BST on Wednesday, 5 July 2023**. The objective of the presentation will be to provide investors with a Company Update on recent developments.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and can arrange to meet ROQUEFORT THERAPEUTICS via:

<https://www.investormeetcompany.com/roquefort-therapeutics-plc/register-investor>

Investors who already follow **ROQUEFORT THERAPEUTICS PLC** on the Investor Meet Company platform will automatically be invited.

**ENDS**

**Enquiries:**

**Roquefort Therapeutics plc**

Stephen West (Chairman) / Ajan Reginald (CEO) +44 (0)20 3918 8633

**Hybridan LLP (Joint Broker)**

Claire Louise Noyce +44 (0)203 764 2341

**Optiva Securities Limited (Joint Broker)**

Christian Dennis

+44 (0)20 3411  
1881

**Buchanan (Public Relations)**

Ben Romney / Jamie Hooper / George Beale

+44 (0)20 7466  
5000

LEI: 254900P4SISIWOR9RH34

**About Roquefort Therapeutics**

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.

Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Roquefort Therapeutics' portfolio consists of five fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:

- Midkine antibodies with significant *in vivo* efficacy and toxicology studies;
- Midkine RNA therapeutics with novel anti-cancer gene editing action;
- Midkine mRNA therapeutics with novel anti-cancer approach;
- STAT-6 siRNA therapeutics targeting solid tumours with significant *in vivo* efficacy; and
- MK cell therapy with direct and NK-mediated anti-cancer action

For further information on Roquefort Therapeutics, please visit [www.roquefortplc.com](http://www.roquefortplc.com) and @RoquefortTherap on Twitter.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage

with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAKZGZVNVVGFZM

Anonymous (not verified)

Investor Presentation via Investor Meet Company

33598408

A

Tue, 06/27/2023 - 07:00

LSE RNS

Company Announcement - General

ROQ